Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Pancreatic Neoplasms 5Recurrence 2Neoplasms 2Carcinoma, Merkel Cell 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Pharmacokinetics 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Triple Negative Breast Cancer 1

Interventions

Cyclophosphamide 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Advanced Triple Negative Breast Cancer × ALT-803 × Clear all
NCT04927884 2024-06-12

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

ImmunityBio, Inc.

Phase 1/2 Terminated
3 enrolled 9 charts
Breast

Advanced Triple Negative Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡